This article is available online at http://www.jlr.org to form a series of biologically active lipid mediators ( 1, 2 ). In the CNS, 12/15-LOX expression has been described throughout the cerebrum, basal ganglia, and hippocampus ( 3, 4 ). Arachidonic acid (AA) is an important component of membrane lipids that can activate several signaling pathways directly by itself or by its metabolites ( 5 ). In nervous tissue, the major enzymatic route for AA metabolism is the 12/15-LOX pathway, and the principal metabolites are 12(S)-HETE and 15(S)-HETE ( 3, 4, 6, 7 ). The biological signifi cance of these metabolites of AA is that they have been proposed to play roles as second messengers in synaptic transmission and they are thought to be involved in learning and memory processes ( 8 ). In addition, 12(S)-HETE is known to act as an inhibitory neuromodulator by reducing voltage-sensitive calcium channel activity ( 9 ) and attenuating glutamate release and affi nity to its receptors ( 10-12 ).
Tissue preparation and nuclear extract isolation
Tissues representing the ipsilateral cortices were harvested at the indicated time after the 90 min ischemia. The tissues were homogenized at 4°C in PBS containing protease inhibitors (10 g/ml soybean trypsin inhibitor, 10 g/ml benzamidine, 10 g/ ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin A, 5 g/ ml antipain, 0.2 mM PMSF, 0.1 mM ethylene diamine tetra-acetic acid). Each sample was homogenized and sonicated on ice. The homogenates were centrifuged at 3,000 g for 15 min at 4°C, and supernatant was obtained and used for total protein analysis.
Nuclear and cytoplasmic fractions were separated with the Active Motif nuclear extract kit (Carlsbad, CA). Isolated brain tissue was fi nely diced and homogenized in ice-cold buffer, and the manufacturer's instructions were followed. Both fractions were applied for Western blot analysis of PPAR ␥ subcellular fractions, and the nuclear extract protein was also used for the assay of DNA binding activity of transcription factors.
Western blot analysis
Proteins were separated on 8% SDS-PAGE, and then transferred onto nitrocellulose membrane. After blocking for 1 h in 0.1% Tween 20/PBS (PBS-T) containing 5% fat-free milk, the blot was incubated with the primary antibody at 4°C overnight. The antibodies were anti-PPAR ␥ (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), anti-12/15-LOX (1:1,000 dilution; Cayman Chemical), anti-COX-2 (1:1,000 dilution; Santa Cruz Biotechnology), or anti-iNOS (1:200 dilution; Santa Cruz Biotechnology). After three washings with PBS-T, the membranes were incubated for 1 h at room temperature with appropriate HRP-conjugated secondary antibodies. The blot was visualized by chemiluminescence. The density of the bands was evaluated regulates genes that are implicated in adipocyte differentiation, lipid and glucose metabolism, and insulin sensitivity. PPAR ␥ also plays a central role in dampening infl ammation via its inhibitory activity on expression of the proinfl ammatory mediators (19) (20) (21) . Notably, treatment of rats with the ligands of PPAR ␥ can signifi cantly protect the brain from ischemic insult by acting against infl ammatory responses (22) (23) (24) (25) (26) (27) . For example, in the transient middle cerebral artery occlusion (MCAO) model of the rat, administration of PPAR ␥ ligands troglitazone or pioglitazone dramatically decreased infarction volume, attenuated microglia activation, and reduced the expression of interleukin-1 ␤ (IL-1 ␤ ), cyclooxygenase-2 (COX-2), and inducible NO synthase (iNOS) ( 22 ) . Another PPAR ␥ agonist, rosiglitazone, also shows potent anti-infl ammatory actions following transient focal ischemia by inhibiting the expression of pro-infl ammatory proteins, myeloperoxidase and intercellular adhesion molecule-1 (ICAM-1), and reduced neutrophil accumulation ( 25 ) . Recently, it has been found that 12(S)-and 15-(S)-HETE can function as ligands of PPAR ␥ in the cells derived from outside the CNS (28) (29) (30) (31) (32) . However, whether they can regulate PPAR ␥ following brain ischemia is still unknown. Moreover, AA itself has been shown to be neuroprotective against oxidative stress on hippocampal slices and furthermore, its neuroprotective effect was completely abolished by PPAR ␥ antagonist, suggesting the involvement of activation of PPAR ␥ ( 33 ). Accordingly, we hypothesize that 12(S)-and 15-(S)-HETE production following cerebral ischemia may be of benefi cial effect by regulating PPAR ␥ . Using a rat model of focal cerebral ischemia, we explored whether exogenous administration of 12(S)-and 15(S)-HETE could activate PPAR ␥ and thus demonstrate the anti-infl ammatory properties in ischemic brain.
EXPERIMENTAL PROCEDURES

Rat model of transient focal ischemia
All studies were conducted after gaining the approval of the Animal Care and Use Committee of Tianjin Medical University. Male Sprague-Dawley rats (Academy of Military Medical Sciences, Beijing, China) weighing from 280 to 330 g were fasted overnight, but were allowed free access to water. Animals were anesthetized with 3% halothane and anesthesia was maintained with 1.5% halothane in 30% oxygen and 68.5% nitrous oxide delivered by facemask. Cerebral ischemic injury was induced by the intraluminal MCAO method as described previously ( 34 ) . Briefl y, the left MCAO was induced by intraluminally advancing a suture with silicone-coated tip to block the origin of the middle cerebral artery . After 90 min occlusion, the animals were again anesthetized with 3% halothane and anesthesia was maintained with 1.5% halothane in 30% oxygen and 68.5% nitrous oxide delivered by facemask. The neck incision was reopened and the suture was removed to allow reperfusion for an indicated duration. Regional cerebral blood fl ow was measured by laser Doppler fl owmetry before and during MCAO, as well as after reperfusion. Systolic arterial blood pressure was monitored through tail-cuff plethysmography. Rectal temperature was continuously maintained (37.5 ± 0.5°C) using a temperature-regulated heating pad and a heating lamp on the surgery table. The femoral artery was catheterized for analysis of blood gases. All by guest, on January 12, 2018 www.jlr.org
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Primary culture of cortical neurons
Primary cortical neurons were prepared from embryonic day 17 Sprague-Dawley rats as described ( 34 ) . Briefl y, cells were dissociated from the cortex, digested with trypsin (Invitrogen), followed by gentle trituration to release cells. After washing, cells were maintained in serum-free B27 neurobasal media (Invitrogen) in a humidifi ed atmosphere of 5% CO 2 /95% air at 37°C. All experiments were performed with neurons that had been in culture for 7-9 days in vitro. Neuron purity was determined using MAP2 labeling, a cell marker for neurons ( 37 ) , which showed >95% purity in cultures.
Plasmids and transient transfection
PPAR ␥ transcriptional activity was evaluated by transient transfection of an expression vector containing the PPRE, the oligonucleotide which PPAR ␥ specifi cally binds to. The oligonucleotide corresponding to PPRE of rat acyl CoA oxidase ( 38 ) was used: 5 ′ -TGACCTTTGTCCT-3 ′ . The 3×PPRE-Luc plasmid was constructed by inserting three copies of the PPRE into the luciferase reporter vector, pGL3-Basic (Promega, Madison, WI) using the enzymes KpnI-Hin dIII. The construct was then confi rmed by DNA sequencing. Transient transfection of neurons was performed as described ( 39 ) using Lipofectamine 2000 (Invitrogen). Briefl y, neurons were seeded in 24-well plates at a density of ‫ف‬ 4-5 × 10 5 cells/well and transiently transfected with 1 g of plasmid DNA in each well. At 24 h after transfection, neuronal cells were then treated with increasing concentrations of 12(S)-HETE or 15(S)-HETE for an additional 24 h. Luciferase activity was measured using the Luciferase Assay system (Promega). Transfection effi ciency was evaluated by the basis of ␤ -galactosidase activity levels. All reporter assays were performed in three replicates in eight independent experiments.
Nitrate plus nitrite measurement
The total amount of NO end production, nitrate plus nitrite (nitrate/nitrite), was measured using a commercially available kit from Cayman Chemical, as described previously ( 34 ) . Briefl y, samples of brain cortical tissue were sonicated in ice-cold PBS (pH 7.4) for 15 s and then centrifuged at 10,000 g for 20 min. The supernatant solution was then ultracentrifuged at 100,000 g for 30 min, followed by fi ltering through a 30 kDa molecular mass cut-off fi lter . Absorbance was measured at 540 nm and converted to nitrate/nitrite content by using a nitrate standard curve. Data are expressed as nanomoles of nitrate/nitrite per milligram of protein.
Measurement of infarct volume
Infarct volumes were measured using 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Chemical) staining. Brains were quickly removed and cut into 2 mm-thick coronal sections. The slices were incubated in 2% TTC at 37°C for 20 min to visualize the infarctions. An image of each slice was analyzed with the Image Pro Plus 6.0 software. To correct for brain swelling in infarction size calculations, the area of uninfarcted tissue in the ischemic hemisphere was measured and subtracted from the area of the intact contralateral hemisphere. The area of infarction from each slice was summed and presented as a percentage of the volume of the uninfarcted hemisphere.
Assessment of neurological defi cits
Assessment of neurological defi cits was performed in animals using a standard scoring system: 0, no defect; 1, failure to extend right forepaw; 2, circling to right; 3, falling to right; and 4, inability to walk spontaneously. densitometrically using the program Quantity One 4.6.2 (Bio-Rad Laboratories, Hercules, CA).
Immunohistochemistry
For single-label immunohistochemistry, frozen sections were permeabilized with 0.3% (v/v) Triton X-100 in PBS for 30 min and blocked with 1% (w/v) BSA in PBS for 1 h, then incubated with primary antibody for 12/15-LOX (1:100, Cayman Chemical) at 4°C overnight. After washing six times in PBS, sections were incubated with FITC-labeled secondary antibody for 1 h at 37°C in the dark. Washing again for six times in PBS, sections were exposed to 4',6-diamidino-2-phenylindole (Beyotime Institute of Biotechnology, China) in the dark at room temperature for 10 min. The fl uorescent images were observed under a fl uorescent microscope. For double fl uorescent staining, fresh-frozen sections were used and incubated with antibodies for 12/15-LOX and marker protein for neurons (neuronal nuclei, NeuN) separately. The fi rst primary antibody was sheep anti-12/15-LOX antibody (1:100 dilution, Cayman Chemical) and the fi rst secondary antibody was FITC-conjugated rabbit anti-sheep IgG (1:200 dilution, Invitrogen, Carlsbad, CA). The second primary antibody was mouse anti-NeuN antibody (1:100 dilution, Chemicon International) and the second secondary antibody was Texas Redconjugated horse anti-mouse IgG (1:200 dilution, Vector Laboratories).The immunoreactivity of 12/15-LOX and NeuN was demonstrated as red and green fl uorescence, respectively. The specifi city of staining was confi rmed using nonimmune control IgG (data not shown). 
Measurement of 12(S)-HETE and 15(S)-HETE
DNA binding activity assay
To assess the level of PPAR ␥ DNA binding induced by 12(S)-HETE or 15(S)-HETE, the TransAM PPAR ␥ transcription factor assay kit (Active Motif) was performed following the manufacturer's instructions. The kit consists of a double-stranded DNA sequence containing the peroxisome proliferator response element (PPRE) immobilized to the wells of a 96-well plate. Nuclear extracts from the ischemic cortex were prepared with the Active Motif nuclear extract kit. Immunoblotting of GAPDH was used to detect cytoplasmic contamination in nuclear extracts. After that, 10 g of nuclear extract protein was applied to the wells and allowed to bind to the PPRE. Then, PPAR ␥ primary antibody and HRP-conjugated secondary antibody were sequentially added. A colorimetric readout was obtained at 450 nm using a Bio-Rad plate reader. The specifi city of the assay was confi rmed by the addition of wild-type and mutated consensus oligonucleotides. The wild-type consensus oligonucleotide can prevent PPAR ␥ binding to the probe immobilized on the 96-well plate and eliminated the signals, whereas the mutated consensus oligonucleotide has little effect on PPAR ␥ binding. Similarly, the DNA binding activity of nuclear factor-B (NF-B) was determined using the TransAM NF-B (p65) transcription factor assay kit (Active Motif) to detect the activation of this transcription factor. 
12(S)-and 15(S)-HETE activate PPAR ␥ in ischemic brain
Fig. 1B , the immunoreactivity of 12/15-LOX was localized primarily to the ischemic border zone at 24 h after MCAO. There was only a little 12/15-LOX expression on the contralateral side. Incubation without the primary antibody resulted in the complete lack of staining (data not shown). To determine whether neurons give rise to the 12/15-LOX signal, we carried out double-labeling experiments with a NeuN. The 12/15-LOX signal was clearly overlaid with strong NeuN immunoreactivity ( Fig. 1C ) , suggesting that the increased 12/15-LOX is likely a result of the neuronal response to ischemic injury.
The 12(S)-and 15(S)-HETE synthesis was also evaluated in the ischemic brain. Consistent with the changes in 12/15-LOX expression, the content of total 12(S)-or 15(S)-HETE in the ipsilateral cortex was time-dependently increased following 90 min ischemia ( Fig. 1D ) .
12(S)-HETE and 15(S)-HETE enhance ischemia-induced PPAR ␥ expression and activity
To ascertain whether PPAR ␥ was regulated by the 12/15-LOX metabolites of AA, exogenous 12(S)-or 15(S)-HETE (10, 15, and 20 g) was given 30 min before the
Statistical analysis
The experimental data are expressed as mean ± SEM and SPSS 11.0 software package was used for data processing. One-way ANOVA was used to compare the means of different groups. Comparisons between two groups were conducted by t -test. A P value <0.05 was considered as statistically signifi cant.
RESULTS
Cerebral ischemia induces elevation of 12/15-LOX expression and metabolites 12(S)-and 15(S)-HETE levels
We fi rst investigated 12/15-LOX, the 12(S)-and 15(S)-HETE-producing enzyme, expression in a rat model of transient focal ischemia induced by MCAO. Following 90 min of ischemia, there was a progressive increase in 12/15-LOX protein level in the ischemic brain (ipsilateral cortex) detected by Western blot analysis ( Fig. 1A ) . This increase occurred as early as 4 h after MCAO and became dramatic from 24 h. To examine the spatial localization of the increase in 12/15-LOX, the immunoreactivity of 12/15-LOX was visualized by immunohistochemical analysis. As illustrated in The whole protein lysate of ischemic cortex was extracted at 24 h after MCAO. The cytosol and nuclear fractions were isolated as described in the Experimental Procedures. PPAR ␥ protein level (A) was measured by Western blot analysis with the whole protein lysate. PPAR ␥ nuclear translocation (B) was evaluated with cytosol and nuclear protein fractions. The bar graph illustrates the densitometric analysis of the related bands. PPAR ␥ DNA binding activity (C) was detected utilizing the PPAR ␥ transcription factor assay kit. Data are expressed as mean ± SEM; n = 8/group; * P < 0.05 versus sham-operated rats (Sham), # P < 0.05 versus vehicle-treated ischemic rats (Veh). D: PPAR ␥ transcriptional activity was observed by luciferase activity assay in cultured cortical neurons transfected with a 3×PPRE-Luc construct. Increasing concentrations of 12(S)-HETE or 15(S)-HETE (0.1, 1, and 10 M) were exogenously added to the cells, and 24 h later the luciferase activity was measured in control (Ctrl) and HETE-treated cells, respectively. n = 8; # P < 0.05 versus control. postischemic infl ammation, which contributes to the progression of brain damage ( 43, 44 ) , whereas PPAR ␥ activation is able to inhibit ischemia-induced infl ammatory response (22) (23) (24) (25) (26) (27) . We therefore evaluated whether exogenous 12(S)-and 15(S)-HETE could suppress the induction of COX-2 and iNOS by ischemic injury. The levels of COX-2 and iNOS proteins were determined by Western blotting and NO release from iNOS was detected by Griess reaction at 24 h after ischemia. As shown in Fig. 3A , the levels of both COX-2 and iNOS increased several-fold in vehicle-treated brains (ipsilateral/ ischemic cortex) as compared with sham-operated nonischemic brains. 12(S)-or 15(S)-HETE treatment (10, 15, and 20 g) signifi cantly attenuated COX-2 and iNOS expression in a dose-dependent manner. The effects of 12(S)-and 15(S)-HETE on iNOS protein levels were also paralleled by a signifi cant reduction in NO levels in the ischemic cortex, as evaluated by the content of NO end product nitrate/nitrite ( Fig. 3B ) . Twenty-four hours after MCAO, we also measured DNA binding activity of NF-B as a marker for NF-B activation. NF-B was increased over 2-fold in the ipsilateral cortex, and the infusion of 12(S)-or 15(S)-HETE (20 g) significantly inhibited ischemia-induced NF-B activation, respectively ( Fig. 3C ) . Administration of 12(S)-or 15(S)-HETE to sham-operated rats had no signifi cant effect on any of the measured markers compared with rats that underwent only sham operation (data not shown).
PPAR ␥ antagonist, GW9662, dose-dependently reverses the suppressive effects of 12(S)-HETE and 15(S)-HETE on COX-2, iNOS, and NF-B
We next investigated whether the anti-infl ammatory effects of 12(S)-and 15(S)-HETE could be reversed by the selective PPAR ␥ antagonist, GW9662. Rats were injected with GW9662 (1, 2, and 4 mg/kg) 30 min before the 12(S)-or 15(S)-HETE treatment (20 g ) and the subsequent MCAO exposure. As illustrated in Fig. 4A , GW9662 dosedependently abrogated the suppressive effects of 12(S)-and 15(S)-HETE on COX-2 and iNOS expression. A similar reversal of the inhibition in NO production was also observed by the treatment of increasing concentrations of GW9662 ( Fig. 4B ). In addition, GW9662 dose-dependently reversed the effect of 12(S)-or 15(S)-HETE-elicited decrease of NF-B activation in ischemic brain ( Fig. 4C ) . These data indicate that the inhibitory effects of 12(S)-and 15(S)-HETE on these pro-infl ammatory mediators are PPAR ␥ dependent. Administration of GW9662 to sham-operated animals had no effect on any of the measured markers (data not shown).
onset of MCAO by icv injection. At 24 h after ischemia, the whole protein lysate and cytosol and nuclear protein fractions were isolated from the ipsilateral cortex. Western blot analysis revealed that ischemic injury induced PPAR ␥ whole protein upregulation ( Fig. 2A ) and cytoplasm-tonuclear translocation ( Fig. 2B ) when compared with the sham-operated control. The exposure to either 12(S)-or 15(S)-HETE could further increase PPAR ␥ total protein level ( Fig. 2A ) and nuclear translocation ( Fig. 2B ) , indicating the activation of PPAR ␥ .
To confi rm this issue, we next performed an ELISAbased assay to examine the specifi c DNA binding activity of PPAR ␥ . For this purpose, the nuclear extract proteins from the rats treated with 12(S)-HETE, 15(S)-HETE, or vehicle were incubated in a 96-well plate immobilized with an oligonucleotide containing the PPRE . As demonstrated in Finally, we assessed PPAR ␥ transcriptional activity in neuronal cells, the cell type in which both 12/15-LOX and PPAR ␥ are predominantly expressed ( 14, 15, 36, 40 ) and PPAR ␥ defi ciency increases susceptibility to brain ischemic damage ( 26 ) . Primary cultured cortical neurons were transiently transfected with a luciferase reporter construct containing three copies of a consensus PPRE and treated with increasing concentrations of 12(S)-or 15(S)-HETE. The luciferase activity was assayed and the results were presented in Fig. 2D . Upon exposure to 12(S)-or 15(S)-HETE (0.1, 1, and 10 M) ( 41, 42 ) , the expression of the reporter gene luciferase was increased in a dose-dependent manner. This observation thus confi rmed that 12(S)-and 15(S)-HETE increase the transcriptional activity of endogenous PPAR ␥ .
The effects of 12(R)-or 15(R)-HETE, the isomers of 12(S)-or 15(S)-HETE with opposing chirality, on PPAR ␥ activation were also examined. The (R) isomers of HETEs failed to show any signifi cant effects on either PPAR ␥ DNA binding activity or PPAR ␥ transcriptional activity (data not shown).
12(S)-HETE and 15(S)-HETE inhibit ischemia-induced upregulation of COX-2 and iNOS, as well as NF-B activation
During brain ischemia, overexpression of COX-2 and iNOS have recently emerged as important determinants of 
12/15-LOX-derived metabolites 12(S)-and 15(S)-HETE
can induce PPAR ␥ expression and activity in ischemic brain and this action is benefi cial to ischemic insult. Indeed, the endogenous activation of PPAR ␥ after cerebral ischemia has been observed previously by us and others ( 26, 40, 45 ) . Furthermore, the infarction size was demonstrated to be increased by the treatment of PPAR ␥ antagonist in the absence of exogenous PPAR ␥ agonist, suggesting that endogenous PPAR ␥ activation is protective and can mitigate the effects of cerebral ischemia ( 40 ) . Consistently, using neuronal PPAR ␥ -defi cient mice, Zhao et al. ( 26 ) showed that neuronal PPAR ␥ defi ciency is associated with augmented ischemic damage in response to MCAO. This data also indicates that an endogenous PPAR ␥ pathway exists in the brain and is important in self-defense of the brain against ischemic injury. Thus, our data might help to explain, in part, the mechanism underlying the PPAR ␥ activation in ischemic brain. However, it is noteworthy that this endogenous activation of PPAR ␥ is likely in relatively low level and unable to confer suffi cient neuroprotection in restricting the infarct development, if without enhancement by the PPAR ␥ activator treated exogenously.
The protective PPAR ␥ activation is also observed by other AA metabolites in the brain. For example, lipoxin A4, one of the AA products formed via 5-LOX, has been shown to have PPAR ␥ agonistic actions and neuroprotection following experimental stroke, and to increase PPAR ␥ transcriptional activity in isolated nuclei from rat brain cortex ( 46 ) . The similar protective effects and PPAR ␥ activation can be produced by 15d-PGJ2, one of the AA-derived products via the cyclooxygenase pathway, treated during brain ischemia in vivo and in vitro ( 36, 47, 48 ) . Even AA, from which 12(S)-and 15(S)-HETE are derived, has been shown to be neuroprotective against oxidative stress on hippocampal slices through a process involving PPAR ␥ signaling ( 33 ) . Therefore, the PPAR ␥ -dependent mechanism is not selective for 12/15-LOX and its 12(S)-and 15(S)-HETE products. Moreover, DHA and its derived products (resolvin D1 and neuroprotectin D1) have also been demonstrated to elicit the beneficial effects in vivo and vitro through a PPAR ␥ -mediated mechanism (49) (50) (51) . These data suggest that many endogenous fatty acid metabolites can activate PPAR ␥ and PPAR ␥ activation underlies their potential neuroprotective actions in the brain. This is also supported by the recent report showing a fatty acid binding pocket in the crystal structure of the PPAR ␥ ligand binding domain. This pocket confers remarkable versatility in ligand binding, such that many different fatty acids and their derivatives can be accommodated ( 52 ).
12(S)-HETE and 15(S)-HETE elicit neuroprotection in rats exposed to focal ischemia
As the anti-infl ammatory effect of PPAR ␥ activation contributes to its protection from cerebral ischemic injury ( 22-27 ), we next investigated whether the two metabolites could afford neuroprotection in rats exposed to MCAO. Infarct volume was measured at 24 h after 90 min MCAO by TTC staining. TTC is actively taken up by cells into mitochondria resulting in a reddish color in normal tissue, whereas the infracted area is colorless. The focal infarcted volume in rats infused with vehicle was about 30% of the hemisphere. The infusion of 12(S)-HETE or 15(S)-HETE (20 g) signifi cantly reduced infarct volume to 18.23% and 20.07%, respectively ( Fig. 5A ) . Neurological defi cits were examined and scored on a grading scale of zero to four. Before MCAO, the neurologic score was normal (score = 0) in all animals. At 24 h after ischemia, vehicletreated rats exhibited signifi cant neurological impairments. 12(S)-HETE or 15(S)-HETE treatment signifi cantly reduced ischemia-induced neurological defi cits (scores: 2.75 ± 0.25 vs. 1.13 ± 0.22 in vehicle and 12-HETE, respectively; 2.75 ± 0.25 vs. 1.38 ± 0.18 in vehicle and 15-HETE, respectively, n = 8, P < 0.05) ( Fig. 5B ). Blood pressure, arterial blood gases, and rectal temperature were equivalent among groups of animals (data not shown).
DISCUSSION
Our fi ndings reported here suggest a possible effect of 12/15-LOX metabolites of AA in ischemic brain: activation of PPAR ␥ and thereby inhibition of infl ammatory response. In the present study, we showed the increments in both 12/15-LOX expression and its metabolites 12(S)-and 15(S)-HETE levels in ischemic brain, which is consistent with the reports of others (13) (14) (15) . Treatment with exogenous 12(S)-and 15(S)-HETE can activate PPAR ␥ , respectively, and potently inhibit the induction of proinfl ammatory factors in a PPAR ␥ -dependent manner. Moreover, the infusion of these metabolites elicits neuroprotection by reducing infarct size and improving neurological defi cits. These fi ndings indicate that the production of 12(S)-and 15(S)-HETE by 12/15-LOX is associated with activation of PPAR ␥ and this event may be protective against cerebral ischemic injury.
There is a considerable literature describing the activation of PPAR ␥ by 12/15-LOX metabolites and, thus, the induction of PPAR ␥ itself and target gene expression in multiple cells and tissues ( 28, 30, 31 ) . These data prompted us to examine the possible link of them in brain tissue in the setting of ischemia. Our fi ndings, for the fi rst time, reported NF-B subunit p65 resulting in the reduction of p65 nuclear translocation ( 27 ) . Accordingly, we assume that the suppression of pro-infl ammatory proteins COX-2 and iNOS by the two metabolites is most likely dependent upon the inhibition of the NF-B pathway.
In addition to PPAR ␥ , several fatty acids also bind to PPAR ␣ ( 72, 73 ) , and activation of this isoform of PPARs can afford neuroprotection from ischemic injury by antiinfl ammatory mechanism ( 74, 75 ) . In the present study, we cannot exclude the possibility that PPAR ␣ activation is involved in the actions of 12(S)-and 15(S)-HETE. Glutamate excitotoxicity is one of the critical components of cerebral ischemic pathology, and 12(S)-and 15(S)-HETE have been proven to be able to protect neurons from glutamate excitotoxicity by reducing calcium infl ux through voltage-gated channels ( 41 ) . Future studies are needed to determine the exact signaling pathway central for the action of 12(S)-and 15(S)-HETE in ischemic injury of the brain.
The data presented here seem to confl ict with the previous reports describing the detrimental effects of 12/15-LOX, and the protective effects of inhibiting 12/15-LOX in ischemic insult of the brain ( 14, 15, 76 ) . Several reasons may explain this discrepancy: 1 ) The biology of 12/15-LOX is complicated, because it has multiple catalytic activities, including hydroperoxidase activity, leukotriene synthase activity, lipoxin synthase activity, and hepoxilin synthase activity [for review see ( 77 ) ]. In addition to producing 12(S)-and 15(S)-HETE, the enzyme is involved in the biosynthesis of lipoxins, hepoxilins, and other products. It is likely that 12/15-LOX-inhibiting or knockout mice are defi cient in a complex mixture of lipid mediators that have been proven to mediate both pro-and antiinfl ammatory pathways [for review see ( 78, 79 ) (80) (81) (82) (83) . Moreover, phospholipid glutathione peroxidase in the 12/15-LOX pathway is a GSH-dependent peroxidase ( 84 ) . Although the reduction of HPETEs to Extracellular free 12(S)-and 15(S)-HETE are known to be incorporated into membrane phospholipids ( 53, 54 ) . The total 12(S)-and 15(S)-HETE detected in ischemic brain ( Fig. 1D ) in our study are supposed to involve both the free and esterifi ed forms of them. However, it should be noted that ischemia induces the activation of phospholipase A2, the enzyme responsible for the massive hydrolysis of membrane phospholipids and release of unesterifi ed fatty acids during cerebral ischemia ( 55, 56 ) . Thus, we speculated that the majority of 12(S)-and 15(S)-HETE in ischemic brain ( Fig. 1D ) may be in free (unesterifi ed) form, because the newly incorporated HETEs will be released by the action of phospholipase A2, if the incorporation of HETEs into membrane phospholipids occurs following ischemic injury.
In the ischemic brain, PPAR ␥ immunoreactivity has been evidenced mainly in neurons ( 36, 40 ) and also in astrocytes, microglia ( 57 ) , and other cells ( 58 ) . In our data, most of the cells with 12/15-LOX staining also demonstrated positive immunoreactivity for the neuronal marker, which is consistent with the previous reports ( 14, 15, 59 ) . Additionally, a G protein-coupled plasma membrane receptor has been identifi ed for 12(S)-and 15(S)-HETE ( 41, 60 ) . Based on these fi ndings, we propose that, like other AA-derived eicosanoids ( 61- The mechanistic basis for the anti-infl ammatory property of PPAR ␥ has been investigated. Among several pathways, inhibition of the transcriptional activity of NF-B is commonly involved ( 27, (64) (65) (66) (67) . NF-B is an essential transcription factor necessary for iNOS and COX-2 gene transcription. The iNOS and COX-2 promoter comprises the binding sites for transcription factor NF-B (68) (69) (70) . Consistently, in the present study, the concomitant suppression in COX-2, iNOS, and NF-B was observed in the ischemic brain by the action of either 12(S)-HETE or 15(S)-HETE. PPAR ␥ has been reported to interfere with the NF-B signaling pathway by preventing the binding of NF-B protein to its target sequences ( 71 ) . Furthermore, PPAR ␥ can interact with by guest, on January 12, 2018 www.jlr.org
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HETEs is very rapid, GSH decrease is able to inhibit the reduction of endogenous HPETE to HETE ( 80, 85 ) . The increases in both HPETE half-life and its toxicity have been observed in neurons under GSH-depleted conditions ( 80, 81 ) . This suggests that toxicity of HPETE may be greatly enhanced in several pathologies in which GSH decrease has been documented, such as stroke. 3 ) In the oxidative injury of neural cells, the enzyme 12/15-LOX has been proven to be able to directly attack mitochondria, leading to cytochrome c release and production of reactive oxygen species . And furthermore, these events can all be replicated by incubation of 12/15-LOX with mitochondria in vitro, without the need to add other cytosolic factors ( 86 ) . These data suggest 12/15-LOX itself could be the source of intracellular reactive oxygen species and the 12/15-LOX metabolites may not be absolutely required for its damaging effects during oxidative stress.
In summary, we have provided data suggesting that following ischemia, the induction of 12/15-LOX metabolites, 12(S)-and 15(S)-HETE, may associate with the activation of PPAR ␥ and downregulate brain ischemia-induced proinfl ammatory signaling . They raise the intriguing possibility that the induction of the 12/15-LOX pathway may exert counterbalancing infl uences on brain ischemic insult, which may be of self-defense biological importance to the ischemic brain. The infarct volume and neurological defi cits were measured at 24 h after MCAO. Data are expressed as mean ± SEM; n = 8/group; # P < 0.05 versus vehicle-treated ischemic rats. A: The infarct volume measured by TTC staining. The bar graph illustrates the infarct volume quantifi ed as percentage area of nonischemic hemisphere. B: Neurological defi cit scores. Neurological defi cits were examined and scored on a grading scale of zero to four, which includes the assessment of motor defi cits contralateral to the injured hemisphere and observation of circling behavior. Rats displaying better neurological outcome received lower neurological scores. 
12(S)-and 15(S)-HETE activate PPAR ␥ in ischemic brain
